TORRANCE, Calif., November 24, 2014 – Emmaus Life Sciences, Inc. (the “Company,” or “Emmaus”), today announced that Dr. Yutaka Niihara, M.D., M.P.H., founder and CEO of Emmaus, will present results of the Company’s Phase 3 clinical trial of its oral pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, in an oral presentation on Sunday, December 7, 2014 at 4:45 p.m. PST, during the 56th American Society of Hematology (ASH) Annual Meeting. The conference is being held December 6-9, 2014 in San Francisco, CA at the Marriott Marquis.